Lambert eaton myasthenic syndrome (lems) antibody testing and treatment recommendations added to nccn clinical practice guidelines for small cell lung cancer (sclc)

Coral gables, fla., aug. 06, 2025 (globe newswire) -- catalyst pharmaceuticals, inc. ("catalyst" or "company") (nasdaq: cprx), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the national comprehensive cancer network® (nccn) clinical practice guidelines in oncology (nccn guidelines®) for small cell lung cancer (sclc) now include new additions involving lambert eaton myasthenic syndrome (lems), amifampridine (firdapse®), and the tests for pq- and n-type voltage-gated calcium channel (vgcc) antibodies.
ETN Ratings Summary
ETN Quant Ranking